Nello Mainolfi - 26 Jul 2021 Form 4 Insider Report for Kymera Therapeutics, Inc. (KYMR)

Role
Chief Executive Officer, Director
Signature
/s/ Bruce Jacobs, as Attorney-in-Fact
Issuer symbol
KYMR
Transactions as of
26 Jul 2021
Net transactions value
-$747,858
Form type
4
Filing time
28 Jul 2021, 16:57:21 UTC
Previous filing
09 Jul 2021
Next filing
02 Aug 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KYMR Common Stock Options Exercise $18,751 +9,015 +2% $2.08* 461,214 26 Jul 2021 Direct
transaction KYMR Common Stock Sale $542,237 -9,015 -2% $60.15 452,199 26 Jul 2021 Direct F1, F2
transaction KYMR Common Stock Options Exercise $8,037 +3,864 +0.85% $2.08* 456,063 28 Jul 2021 Direct
transaction KYMR Common Stock Sale $232,410 -3,864 -0.85% $60.15 452,199 28 Jul 2021 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KYMR Stock Option (Right to Buy) Options Exercise $0 -9,015 -7.1% $0.000000 117,710 26 Jul 2021 Common Stock 9,015 $2.08 Direct F3
transaction KYMR Stock Option (Right to Buy) Options Exercise $0 -3,864 -3.3% $0.000000 113,846 28 Jul 2021 Common Stock 3,864 $2.08 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2020.
F2 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $60.00 to $60.61. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F3 The shares underlying this stock option shall vest upon the achievement of specified performance-based milestones.